公开(公告)号：US20210025900A1

公开(公告)日：2021-01-28

申请号：US16923043

申请日：2020-07-07

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/68 ,  C07K16/28

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

公开(公告)号：US20250020660A1

公开(公告)日：2025-01-16

申请号：US18426232

申请日：2024-01-29

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/68 ,  C07K16/28

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

公开(公告)号：US11686734B2

公开(公告)日：2023-06-27

申请号：US16923043

申请日：2020-07-07

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/68 ,  C07K16/28

CPC classification number: G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).